Promoter entity plans to delist Fresenius Kabi Oncology from the bourses

18 Apr 2013 Evaluate

Fresenius Kabi Oncology’s (FKOL) promoter entity Fresenius Kabi (Singapore) (FKSL) is planning to delist its Indian arm through acquiring 19% stake held by the public. FKSL intends to pay an indicative price of upto Rs 130 per share to acquire the scrips offered to it in the delisting offer.

Fresenius Kabi (Singapore) holds 81% of the total stake in the Indian arm.

Fresenius Kabi Oncology manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.

Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.